Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771711 | 0.86 | PGR (0.52) | AR | |
| SCHEMBL3299928 | 0.79 | KIF11 (0.52) | KIF11CA12CA9 | |
| SCHEMBL30349881 | 0.78 | MAPT (0.61) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL8900835 | 0.78 | KIF11 (0.58) | KIF11CA12CA9CTSVCTSL | |
| SCHEMBL31081636 | 0.77 | CA12 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL31169728 | 0.77 | CA12 (0.58) | ARKIF11CA12CA9CTSV | |
| SCHEMBL4469615 | 0.77 | CA12 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL20183771 | 0.77 | CA12 (0.58) | ARKIF11CA12CA9CTSV | |
| SCHEMBL1771152 | 0.76 | AR (0.69) | AR | |
| SCHEMBL4132327 | 0.76 | KIF11 (0.86) | KIF11CA12CA9CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7696246-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1603882-A2 | UREA AND THIOUREA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20040266820-A1 | Urea and thiourea derivatives | DU DANIEL Y (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004072044-A2 | UREA AND THIOUREA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885KIF11 4318/4885CA12 2394/4885 |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885KIF11 4542/4885CA12 2341/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885KIF11 4590/4885CA12 2577/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885KIF11 4542/4885CA12 2341/4885 |
| US-20040266820-A1 | Urea and thiourea derivatives | SHBG, ZP1, ZYX | AR 25/4885KIF11 3044/4885CA12 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.